Sumitomo Dainippon gets rights to Poxel's imeglimin in thirteen Asian countries
Poxel SA licensed Sumitomo Dainippon Pharma Co. Ltd. rights to develop and commercialize its Phase II Type II diabetes candidate imeglimin in Japan, China, South Korea, Taiwan, Indonesia, Vietnam, Thailand, Malaysia, the Philippines, Singapore, Myanmar, Cambodia, and Laos.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com